Product Information
NEXLIZET 180-10 MG TABLET is a brand product labeled by Esperion Therapeutics, Inc., priced at $13.7964 per EA under NDC 72426081803. Its NADAC has been published 311 times since Oct 21, 2020.
FDA first approved this application on Feb 26, 2020.
Strength
180; 10 mg/1; mg/1
Manufacturer
Esperion Therapeutics, Inc.NDC
72426081803
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
BEMPEDOIC ACID; EZETIMIBEApproval Type
New Drug (NDA)
FDA Application
NDA211617FDA Approved
2/26/2020
On Market Since
3/9/2020
Pharmacological Classes
Price Statistics
The NADAC for NEXLIZET 180-10 MG TABLET has been published 311 times since Oct 21, 2020, and over the history we have for it it has risen 30.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $13.7964 per EA |
|---|---|
| All-time high | $13.8411 (May 13, 2026) |
| All-time low | $10.5564 (Oct 21, 2020) |
| 52-week high | $13.8411 |
| 52-week low | $13.4352 |
| Median price | $12.6664 |
| Average price | $12.5963 |
| Largest weekly change | +9.9% (Jan 12, 2022) |
| Weeks tracked | 311 |
| Tracking since | Oct 21, 2020 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Bempedoic Acid and Ezetimibe market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Esperion Therapeutics, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Bempedoic Acid and Ezetimibe market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Dietary Cholesterol Absorption Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of NEXLIZET 180-10 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for NEXLIZET 180-10 MG TABLET, manufactured by Esperion Therapeutics, Inc., is $13.7964 per EA (NDC 72426081803), effective Sep 30, 2026.
How has the price of NEXLIZET 180-10 MG TABLET changed over time?
Over the history we have for it, the NADAC for NEXLIZET 180-10 MG TABLET has risen 30.7%. It has been tracked across 311 weekly CMS publications since Oct 21, 2020.
What are the highest and lowest recorded NADAC prices for NEXLIZET 180-10 MG TABLET?
Since Oct 21, 2020, the NADAC for NEXLIZET 180-10 MG TABLET has ranged from a low of $10.5564 (Oct 21, 2020) to a high of $13.8411 (May 13, 2026), with a median of $12.6664 per EA.
Are there cheaper alternatives to NEXLIZET 180-10 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of NEXLIZET 180-10 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures NEXLIZET 180-10 MG TABLET?
NEXLIZET 180-10 MG TABLET (NDC 72426081803) is labeled by Esperion Therapeutics, Inc., and CMS classifies it as a brand product.